Cleavage vs. Cover-up: New Study Sponsored By Violet® iodine Reveals 73 percent of American Women Aren't Looking to Show-off 'The Girls'
PR Newswire - Wed Jul 08, 8:22AM CDT
If you've got them, flaunt them, right? Well, that's now only true for 27% of American women according to a new survey conducted by Newlio for Violet® iodine. In fact, this summer, the top swimsuit choice will be a one-piece (51 percent), followed by a tankini (18 percent), and a bikini (13 percent). Modesty may be on the rise this season, but the majority of women (73%) are perfectly happy with their cup sizes.
BPMX: 2.50 (+0.05)
BioPharmX Corporation Closes Underwritten Public Offering of Common Stock
PR Newswire - Wed Jul 01, 6:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX) today announced the closing of its previously announced underwritten public offering of 3,636,364 shares of its common stock at a price to the public of $2.75 per share. BioPharmX has granted the underwriters a 30-day option to purchase up to 545,454 additional shares of common stock at the public offering price.
BPMX: 2.50 (+0.05)
U.S. IPO Weekly Recap: Year's Hottest Deal Pops 186% In Year's Most Active Week With 13 IPOs
Renaissance Capital IPO Research - at Seeking Alpha - Sat Jun 27, 11:49AM CDT
Things just got Seres in the IPO market. Thirteen companies went public this past week , more than any week since October 2014. Seres Therapeutics skyrocketed 186% on its debut - the highest first-day pop since January 2014. The thirteen IPOs...
XTLY: 8.29 (+0.04), TRU: 24.45 (+0.12), CATB: 14.38 (+1.83), GNRT: 13.62 (-0.06), GPP: 14.89 (+0.60), GKOS: 30.75 (+0.51), APPF: 14.79 (+0.68), YECO: 5.09 (+0.42), MCRN: 19.76 (+0.28), LNTH: 6.91 (-0.09), BPMX: 2.50 (+0.05), ALRM: 16.15 (-0.30), MCRB: 40.90 (+1.06)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Jun 25, 11:45AM CDT
CNXR: 11.57 (+0.90), TROV: 9.63 (+0.20), CNR: 1.00 (-0.01), CVSL: 1.18 (+0.06), NR: 7.91 (+0.08), SSE: 3.45 (-0.26), ATAI: 4.65 (+0.08), KIQ: 2.75 (-0.09), OPGN: 3.43 (+0.08), DSKX: 3.18 (-0.05), TRU: 24.45 (+0.12), HCA: 92.97 (+1.33), THC: 59.43 (+0.48), ISSC: 3.00 (unch), IKGH: 2.02 (-0.10), DPW: 0.93 (-0.02), SIXD: 12.20 (+1.33), BPMX: 2.50 (+0.05), OGEN: 1.62 (+0.04)
BIOPHARMX CORPORATION UPLISTS TO NYSE MKT (BPMX)
PR Newswire - Thu Jun 25, 6:00AM CDT
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focused on the development of proprietary drug delivery products, today announced the pricing of a public offering of 3,636,364 shares of common stock at a price to the public of $2.75 per share for an aggregate offering amount of $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the company. In addition, BioPharmX has granted the underwriters a 30-day option to purchase up to 545,454 additional shares of common stock at the public offering price. In conjunction with the pricing of the offering, the company is simultaneously uplisting to the NYSE MKT today, and begins trading under the ticker symbol "BPMX." All shares of common stock to be sold in the offering are being offered by BioPharmX. The offering is expected to close on or about June 30, 2015, subject to customary closing conditions.
BPMX: 2.50 (+0.05)
BioPharmX begins trading on the NYSE MKT
M2 - Thu Jun 11, 12:15PM CDT
Companies mentioned in this article: BioPharmX Corporation (OTCQB: BPMX), DAVIDsTEA Inc. (NASDAQ: DTEA), Evolent Health Inc. (NYSE: EVH), EndoChoice Holdings (NYSE: GI), and PennTex Midstream Partners, LP (NASDAQ: PTXP)
DTEA: 20.51 (+1.31), EVH: 19.65 (-0.09), BPMX: 2.50 (+0.05), PTXP: 18.95 (-0.03), GI: 15.09 (+0.09)
BioPharmX on deck for IPO
Seeking Alpha - at Seeking Alpha - Thu Jun 11, 12:06PM CDT
BPMX: 2.50 (+0.05)
BioPharmX to uplist to the NYSE MKT, via APO, while PennTex is the next IPO
M2 - Tue Jun 02, 8:26AM CDT
Companies mentioned in this article: BioPharmX Corporation (OTCQB: BPMX), Source Financial Inc. (SRCF), PennTex Midstream Partners, LP (NASDAQ: PTXP), Memorial Resource Development Corp. (NASDAQ: MRD), and Shopify Inc. (NYSE: SHOP)
SHOP: 29.60 (+0.54), MRD: 17.62 (-0.16), BPMX: 2.50 (+0.05), PTXP: 18.95 (-0.03)
BioPharmX Corporation Announces Violet(TM) Iodine is Now Available at The Vitamin Shoppe®
PR Newswire - Mon Apr 20, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), makers of Violet(TM) iodine, the new, once-daily, non-prescription iodine supplement for the relief of premenstrual breast discomfort*, today announced that new Violet iodine is now available at The Vitamin Shoppe®.
BPMX: 2.50 (+0.05)
BioPharmX Corporation Files Registration Statement For Proposed Public Offering
PR Newswire - Thu Apr 09, 4:37PM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of proprietary drug delivery products, today announced that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) relating to a proposed public offering of its common stock. The number of shares to be offered by BioPharmX and the price range for the offering have not yet been determined.
BPMX: 2.50 (+0.05)
BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors
PR Newswire - Mon Mar 30, 8:30AM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Stephen Morlock, a seasoned financial executive and retail industry veteran, to its board of directors. Mr. Morlock's background will assist the company as it continues to expand its national roll-out of Violet iodine, the new, once-daily, non-prescription pill for relief of premenstrual breast discomfort, and he will serve as an independent board member on BioPharmX Corporation's audit, compensation and nominating and corporate governance committees.
BPMX: 2.50 (+0.05)
BioPharmX Corporation Completes Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
PR Newswire - Wed Mar 18, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), a specialty pharmaceutical company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that its planned pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) was held on March 11, 2015, as scheduled. The pre-IND meeting focused on the company's topical antibiotic acne compound currently under development and the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
BPMX: 2.50 (+0.05)
BioPharmX Announces Violet(TM) Iodine Now Available at Leading National Retailer
PR Newswire - Tue Mar 10, 7:00AM CDT
BioPharmX Corporation (OTCQB: BPMX), makers of Violet(TM) iodine, the new, once-daily, non-prescription pill for the relief of premenstrual breast discomfort, today announced the first-of-its-kind product has added a major U.S. drugstore chain to its retail partners. The daily supplement is available now and will be offered exclusively in the feminine care aisle.
BPMX: 2.50 (+0.05)
BioPharmX names Michael Hubbard as chair of audit committee
M2 - Fri Jan 30, 2:10AM CST
Biotechnology company BioPharmX (OTCBB:BPMX) disclosed on Wednesday the addition of Michael Hubbard as a new independent member of its board of directors, increasing the board's total number of members to four.
BPMX: 2.50 (+0.05)
BioPharmX Corporation Appoints Michael Hubbard To Its Board Of Directors
PR Newswire - Wed Jan 28, 10:30AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced the appointment of Michael Hubbard as a new independent member of its board of directors. Hubbard, a seasoned financial executive with a career in public accounting and auditing, will also lead the company's audit committee. Hubbard's appointment brings the board's total number of members to four.
BPMX: 2.50 (+0.05)
BioPharmX Corporation Granted Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution
PR Newswire - Mon Jan 12, 9:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has been granted a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the company's topical antibiotic acne compound currently under development. The meeting, currently scheduled for March 2015, is expected to focus on the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials.
BPMX: 2.50 (+0.05)
BioPharmX Corporation To Present At OneMed Forum SF 2015 Conference
PR Newswire - Thu Jan 08, 9:00AM CST
BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that Jim Pekarsky, chief executive officer and co-founder of BioPharmX, will present at the OneMed Forum SF 2015 Conference on Monday, January 12 at 3:00 p.m. PST at the Marriott Marquis in San Francisco.
BPMX: 2.50 (+0.05)
UPM Pharmaceuticals to Manufacture BioPharmX's First Commercially Available Product
PR Newswire - Wed Dec 10, 8:00AM CST
UPM Pharmaceuticals, a division of Gregory Pharmaceutical Holdings, Inc., has reached an agreement with BioPharmX, Inc. (OTCQB: BPMX) to commercially manufacture solid dose iodine supplement tablets for the consumer products sector. The tablets will be manufactured at UPM's 475,000 square-foot manufacturing facility in Bristol, Tennessee, under a commercial supply agreement. Terms of the agreement were not disclosed.
BPMX: 2.50 (+0.05)